TEFIBAZUMAB: A COMPREHENSIVE INVESTIGATION INTO INH-H2002 AND ITS PROMISE

Tefibazumab, previously known as INH-H2002, represents a novel medical approach targeting complement factor H, specifically its ability to interact with C5. This immunoglobulin is designed to prevent the development of the C5b-9 membrane attack complex, a significant driver of tissue damage in va